Mainstay Medical is focused on commercializing an implantable neurostimulation system for the treatment of chronic low back pain
Oxford Finance LLC (“Oxford”), a specialty finance firm that provides senior debt to life sciences and healthcare services companies worldwide, has announced the closing of a $50 million senior secured term loan with Mainstay Medical Holdings plc (“Mainstay” or “the Company”), a medical device company focused on commercializing an innovative implantable restorative neurostimulation system, ReActiv8®, for the treatment of disabling mechanical chronic low back pain (“CLBP”).
“Oxford is proud to support a Company using a novel method to treat an underserved medical issue which has the potential to help millions of people who suffer from chronic back pain.”
ReActiv8 is an active implantable medical device that stimulates nerves responsible for activating a key muscle involved in stabilizing the lower back. ReActiv8 is designed to provide therapy for people whose lives are significantly impacted by intractable, mechanical CLBP. Contraction of the muscle can lead to restoration of control over time, allowing the back to recover from CLBP.
Read More: Gilded Launches Mass Pay, Enabling Businesses to Pay Employees in Crypto
“Mainstay is preparing to launch the ReActiv8 device in the US to address the large population of mechanical CLBP patients who have limited treatment options,” said Christopher A. Herr, senior managing director at Oxford Finance. “Oxford is proud to support a Company using a novel method to treat an underserved medical issue which has the potential to help millions of people who suffer from chronic back pain.”
Read More: Clearbanc Rebrands to Clearco, Announces US$100 Million Series C Funding
